OncoSec Medical Inc (ONCSQ)

[guti]

I will gladly answer all your questions if necessary, but the laugh before you asking makes it  seem like sarcasm. Someone that has followed Oncosec for more than a year would know the answers offered by different forums or at company conferences,  and should be part of the research necessary by anyone investing their time or money. More importantly when it comes to cancer, is knowing the difference between first and second line therapy or a last resort. For now, the study I referenced  is of last resort. Also, don't get confused, if EP IL-12 with Keytruda can help some non responders, it's a given that responders will benefit as well.

Combination with IL-12 has already been tested with standard of care (first line therapy) in preclinical studies and results are positive. You can start the research yourself by reading my next post.